Flynn Campbell D, Curran Neil P, Chan Stephanie, Zegri-Reiriz Isabel, Tauron Manel, Tian David H, Pettersson Gosta B, Coselli Joseph S, Misfeld Martin, Antunes Manuel J, Mestres Carlos A, Quintana Eduard
Department of Cardiothoracic Surgery, St George Hospital, Sydney, Australia.
Heart Failure and Heart Transplant Unit, Cardiology Department, Hospital de la Santa Creu i Santa Pau, Barcelona, Spain.
Ann Cardiothorac Surg. 2019 Nov;8(6):587-599. doi: 10.21037/acs.2019.10.03.
Infective endocarditis (IE) is an infection involving either native or prosthetic heart valves, the endocardial surface of the heart or any implanted intracardiac devices. IE is a rare condition affecting 3-15 patients per 100,000 population. In-hospital mortality rates in patients with IE remain high at around 20% despite treatment advances. There is no consensus recommendation favoring either bioprosthetic valve or mechanical valve implantation in the setting of IE; patient age, co-morbidities and preferences should be considered selecting the replacement prosthesis.
A systematic review and meta-analysis of studies reporting the outcomes of patients undergoing bioprosthetic or mechanical valve replacement for infective endocarditis with data extracted for overall survival, valve reinfection rates and valve reoperation.
Eleven relevant studies were identified, with 2,336 patients receiving a mechanical valve replacement and 2,057 patients receiving a bioprosthetic valve replacement. There was no significant difference for overall survival between patients treated with mechanical valves and those treated with bioprosthetic valves [hazard ratio (HR) 0.94, 95% confidence interval (CI): 0.73-1.21, P=0.62]. There was no significant difference in reoperation rates between patients treated with a bioprosthetic valve and those treated with a mechanical valve (HR 0.82, 95% CI: 0.34-1.98, P=0.66) and there was no significant difference in the rate of valve reinfection rates (HR 0.95, 95% CI: 0.48-1.89, P=0.89).
The presence of infective endocarditis alone should not influence the decision of which type of valve prosthesis that should be implanted. This decision should be based on patient age, co-morbidities and preferences.
感染性心内膜炎(IE)是一种涉及天然或人工心脏瓣膜、心脏内膜表面或任何植入的心内装置的感染。IE是一种罕见疾病,每10万人中有3 - 15人患病。尽管治疗取得了进展,但IE患者的住院死亡率仍高达20%左右。在IE情况下,对于生物瓣膜或机械瓣膜植入,尚无一致推荐;选择置换瓣膜时应考虑患者年龄、合并症和偏好。
对报告感染性心内膜炎患者接受生物瓣膜或机械瓣膜置换结果的研究进行系统综述和荟萃分析,提取总体生存率、瓣膜再感染率和瓣膜再次手术的数据。
确定了11项相关研究,2336例患者接受机械瓣膜置换,2057例患者接受生物瓣膜置换。接受机械瓣膜治疗的患者与接受生物瓣膜治疗的患者在总体生存率上无显著差异[风险比(HR)0.94,95%置信区间(CI):0.73 - 1.21,P = 0.62]。接受生物瓣膜治疗的患者与接受机械瓣膜治疗的患者在再次手术率上无显著差异(HR 0.82,95% CI:0.34 - 1.98,P = 0.66),在瓣膜再感染率上也无显著差异(HR 0.95,95% CI:0.48 - 1.89,P = 0.89)。
仅感染性心内膜炎的存在不应影响植入何种类型瓣膜假体的决策。该决策应基于患者年龄、合并症和偏好。